5-异氰基-2-甲基吡啶 | 732245-99-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-异氰基-2-甲基吡啶
• 中文别名: 5-异氰酸酯-2-甲基吡啶
• 英文名称: 5-isocyanato-2-methylpyridine
• 英文别名: 5-Isocyanato-2-methyl-pyridine；2-methyl-5-isocyanatopyridine；3-isocyanato-6-methylpyridine
• CAS: 732245-99-7
• 化学式: C₇H₆N₂O
• 分子量: 134.137
• InChiKey: WWBMYUQLNXLJJC-UHFFFAOYSA-N

物化性质

• 沸点：
  203.9±28.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  29333990
• 储存条件：
  -20°C

反应信息

• 作为反应物：
  描述：

  5-异氰基-2-甲基吡啶 在 palladium hydroxide on carbon 氢气 作用下， 以 甲醇 、 四氢呋喃 为溶剂， 50.0 ℃ 、413.69 kPa 条件下， 反应 0.5h， 生成 4-(4-fluoro-3-(3-(6-methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Compounds, compositions and methods

  摘要：

  某些替代脲衍生物能选择性地调节心脏肌丝，例如通过增强心肌肌球蛋白，并且在治疗包括充血性心力衰竭在内的收缩性心力衰竭方面具有用处。

  公开号：

  US20060014761A1
• 作为产物：
  描述：

  6-甲基-3-吡啶羰基叠氮化物 以 甲苯 为溶剂， 反应 1.5h， 生成 5-异氰基-2-甲基吡啶
  参考文献：
  名称：

  (+)-(2R,5S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an Orally Potent and Peripherally Selective Nonsteroidal Androgen Receptor Antagonist

  摘要：

  A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

  DOI：

  10.1021/jm050293c
• 作为试剂：
  描述：

  5-异氰基-2-甲基吡啶 、 methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate 在 5-异氰基-2-甲基吡啶 作用下， 以86的产率得到4-[[2-氟-3-[N'-(6-甲基吡啶-3-基)脲基]苯基]甲基]哌嗪-1-羧酸甲酯
  参考文献：
  名称：

  Compounds, compositions and methods

  摘要：

  某些取代脲衍生物可以选择性地调节心脏肌肉纤维，例如通过增强心肌肌球蛋白的作用，这些物质在治疗收缩性心力衰竭，包括充血性心力衰竭方面非常有用。

  公开号：

  US07507735B2

文献信息

• Novel lapachone compounds and methods of use thereof
  申请人：Ashwell Mark A.

  公开号：US20090105166A1

  公开（公告）日：2009-04-23

  The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).

  本发明提供了一种新型的三环螺-氧杂硫杂萘醌衍生物，一种制造该衍生物的方法，以及利用该衍生物诱导细胞死亡和/或抑制癌症或前癌细胞增殖的应用。本发明的萘醌衍生物与被称为β-拉帕醇（3,4-二氢-2,2-二甲基-2H-萘(1,2-b)吡喃-5,6-二酮）的化合物有关。
• Oxindole derivatives
  申请人：Luk Kim-Chun

  公开号：US20060293319A1

  公开（公告）日：2006-12-28

  The invention describes compounds of the general formula I or the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and X are herein described, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show activity as antiproliferative agents and may be especially useful for the treatment of cancer.

  这项发明描述了一般式I的化合物或其药用盐，其中R1、R2、R3和X在此处描述，以及它们的制备方法、含有它们的药物以及将这些化合物用作药用活性剂的用途。这些化合物显示出抗增殖剂的活性，可能特别适用于癌症的治疗。
• ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
  申请人：Ghiron Chiara

  公开号：US20100016343A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。提供的化合物可以影响神经系统、精神病和/或炎症系统等方面。
• 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL
  申请人：GRÜNENTHAL GMBH

  公开号：US20180078541A1

  公开（公告）日：2018-03-22

  The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.

  本发明涉及一种符合通用式（I）的化合物，该化合物作为FPR2的调节剂，并可用于治疗和/或预防至少部分由FPR2介导的疾病。
• Palladium-Catalyzed Cross-Coupling of Aryl Chlorides and Triflates with Sodium Cyanate: A Practical Synthesis of Unsymmetrical Ureas
  作者：Ekaterina V. Vinogradova、Brett P. Fors、Stephen L. Buchwald

  DOI：10.1021/ja305212v

  日期：2012.7.11

  chlorides and triflates with sodium cyanate is reported. The protocol allows for the synthesis of unsymmetrical N,N'-di- and N,N,N'-trisubstituted ureas in one pot and is tolerant of a wide range of functional groups. Insight into the mechanism of aryl isocyanate formation was gleaned through studies of the transmetalation and reductive elimination steps of the reaction, including the first demonstration

  报道了一种钯催化芳基氯和三氟甲磺酸酯与氰酸钠交叉偶联的有效方法。该协议允许在一锅中合成不对称的 N,N'-di-和 N,N,N'-三取代脲，并且可以容忍多种功能组。通过对反应的金属转移和还原消除步骤的研究，包括从芳基钯异氰酸酯络合物中还原消除生成异氰酸芳基酯的首次演示，深入了解了芳基异氰酸酯的形成机制。